Vicore Pharma completes enrolment of the global Phase 2b ASPIRE trial evaluating buloxibutid in idiopathic pulmonary fibrosis with topline results are expected in mid-2027 - Meet them in September

Calluna Pharma completes enrolment six months ahead of schedule for its global Phase 2 AURORA study of CAL101 for idiopathic pulmonary fibrosis with topline results are expected in Q1 2027

Redefining Clinical Endpoints in Pulmonary Fibrosis & Moving Beyond FVC to Capture True Treatment Impact

8:29 am - Thursday 1st October 2026

Redefining Clinical Endpoints in Pulmonary Fibrosis & Moving Beyond FVC to Capture True Treatment Impact

Redefining Clinical Endpoints in Pulmonary Fibrosis & Moving Beyond FVC to Capture True Treatment Impact

Venue

Map

Contact

Join Our Team

About Us

Explore Our Conferences

Stay Connected

Search

Organized By